Citius Pharmaceuticals is trading at $0.49, up 9.01%, after its majority-owned subsidiary reported preliminary fourth-quarter LYMPHIR wholesaler shipments of 792 units, up 120% from the prior quarter.
- Institutional vial orders totaled 950, versus 926 previously; 54 institutions ordered LYMPHIR.
- Shipment figures were preliminary and unaudited; complete fiscal 2026 results are expected in December.
- The catalyst was company-specific; no reliable live-volume figure was established.